|
|
News Breaks | | | | January 4, 2013 | | 07:55 EDT |  | VRX | Valeant sees Q4 cash EPS $1.18-$1.23, consensus $1.25
Sees Q4 revenue >$900M, consensus $966M. Says Q4 guidance remains unchanged. Sees adjusted cash flows from ops $330M-$430M. Says Medicis impact expected to be immaterial. Comments from slides that will be presented on the 2013 financial guidance conference call. | |
|
News For VRX From The Last 14 Days Check below for free stories on VRX the last two weeks. |
|
|
| May 17, 2013 | | 14:48 EDT |  | VRX | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
 Subscribe for More Information | | | 13:56 EDT |  | VRX | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. | | | May 15, 2013 | | 19:37 EDT | | VRX | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | May 14, 2013 | | 17:48 EDT | | VRX | Lone Pine gives quarterly update on stakes
NEW STAKES: Valeant Pharmaceuticals (VRX), Virgin Media (VMED), Thermo Fisher Scientific (TMO), CME Group (CME), and Liberty Media (LMCA). INCREASED STAKES: Mead Johnson Nutrition (MJN), News Corp (NWSA), Intuitive Surgical (ISRG), Monsanto (MON), and Qualcomm (QCOM). DECREASED STAKES: Cognizant Technology Solutions (CTSH), Equinix (EQIX), Ralph Lauren (RL), Disney (DIS), and Oceaneering International (OII). LIQUIDATED STAKES: Facebook (FB), Crown Castle (CCI), Accretive Health (AH), Informatica (INFA), and NetEase (NTES). | | | 13:55 EDT | | VRX | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information | | | May 10, 2013 | | 17:03 EDT | | VRX | Valeant announces information regarding continuance proposal
Subscribe for More Information | |
|
|
|
|
|
|
